Asha's Focus: Devasting Neurological Conditions
Neurodegeneration
Neuro-oncology
Neuromuscular
Neurovascular
& Stroke
Disease Indications
We levarage our expertise in computational and medicinal chemistry paired with validated biological drivers of disease to design novel compounds for disease with high unmet medical need. Our mission is to eliminate neurological disease.
Mitochondrial Fragmentation:
A Central Contributor to Neurological Pathologies
Maintaining the health and efficiency of the mitochondrial network is of vital importance to cellular health and function. Beyond its role in energy production, the mitochondrial network is a critical signaling hub that greatly influences how the cell responds to harmful stimuli, regardless of what triggers the original pathological change. One method of signaling is to dynamically fragment or fuse the network to signal global changes in the cell.
Hyperfragmentation has been found to be a key contributor to neurological disease pathology and progression and is a pathogenic feature in diseases including Parkinson's Disease, Alzheimer's Disease, Stroke, and others.
Mitochondrial Fragmentation: A Universal Therapeutic Target
Mitochondrial fragmentation has been observed in the majority of neurological disorders, and is now recognized as a critical driver of pathology. While there are many factors that can trigger a diseased state, the symptoms of different neurological disorders maintain similarities due to the underlying pathway failure being conserved.
Mitochondrial Fragmentation: Beyond the Brain
In addition to being a key driver of disease pathology in the brain, mitochondrial fragmentation has been implicated in over 100 diseases across multiple organ systems. Therapeutic applicability for tareting mitochondrial fragmentation goes well beyond neurological disease and is a potential disease modifying therapeutic approach for many conditions.
ASHA Assets: Two Novel Therapeutics, One Goal
